U.S. patent application number 10/207041 was filed with the patent office on 2003-03-06 for human stem cells originated from human amniotic mesenchymal cell layer.
Invention is credited to Sakuragawa, Norio, Uchida, Saiko.
Application Number | 20030044977 10/207041 |
Document ID | / |
Family ID | 19073925 |
Filed Date | 2003-03-06 |
United States Patent
Application |
20030044977 |
Kind Code |
A1 |
Sakuragawa, Norio ; et
al. |
March 6, 2003 |
Human stem cells originated from human amniotic mesenchymal cell
layer
Abstract
Neural stem cells which can be provided stably and which are
free from the problem of compatibility in transplantation are
disclosed. The stem cells are separated from human amniotic
mesenchymal cell layer and express vimentin, nestin and BrdU which
are markers of neural stem cells. The stem cells can also be
differentiated to cells expressing alkaline phosphatase, that is,
osteocytes, and to cells expressing collagen type II, that is,
chondrocytes.
Inventors: |
Sakuragawa, Norio; (Tokyo,
JP) ; Uchida, Saiko; (Tokyo, JP) |
Correspondence
Address: |
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH
VA
22040-0747
US
|
Family ID: |
19073925 |
Appl. No.: |
10/207041 |
Filed: |
July 30, 2002 |
Current U.S.
Class: |
435/368 |
Current CPC
Class: |
C12N 2501/11 20130101;
C12N 2501/115 20130101; C12N 5/0655 20130101; C12N 5/0623 20130101;
C12N 2506/08 20130101; C12N 5/0654 20130101 |
Class at
Publication: |
435/368 |
International
Class: |
C12N 005/08 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 10, 2001 |
JP |
2001-243907 |
Claims
1. Cells separated from human amniotic mesenchymal cell layer,
which express vimentin, nestin and BrdU that are markers of neural
stem cells.
2. Cells separated from human amniotic mesenchymal cell layer,
which express nestin and musashi-1 that are markers of neural stem
cells.
Description
BACKGROUND OF THE INVENTION
[0001] I. Field of the Invention
[0002] The present invention relates to novel neural stem cells
separated from human amniotic membrane. The cells according to the
present invention are useful as sources of the substances produced
by nerve cells. Further, the cells according to the present
invention are useful as drug delivery systems of the substances
produced by nerve cells by transplanting the cells in the brain of
a patient suffering from an intractable nervous disease such as
Parkinson's disease or metabolic nervous diseases.
[0003] II. Description of the Related Art
[0004] Multifunctional stem cells are undifferentiated cells which
can differentiate into cells constituting various tissues, which
are important in the fields of organ reconstruction and tissue
engineering. As the stem cells, myeloid stem cells obtained from
bone marrow and cord blood stem cells are known. However, these
stem cells have problems in that they are not supplied stably. It
was reported this year that a large amount of multifunctional stem
cells may be recovered from human placenta. However, since placenta
is originated from mother, when transplanting the cells
differentiated from the stem cells originated from placenta, the
compatibility of the cells must be checked in order to prevent
rejection, and the cells cannot be transplanted to the patient who
is not compatible with the cells, which is problematic.
SUMMARY OF THE INVENTION
[0005] An object of the present invention is to provide neural stem
cells which can be supplied stably and which is free from the
problem about the compatibility in transplantation.
[0006] The present inventors intensively studied to discover that
neural stem cells exist in the mesenchymal cell layer of human
amnion, thereby completing the present invention.
[0007] That is, the present invention provides cells separated from
human amniotic mesenchymal cell layer, which express vimentin,
nestin and BrdU that are markers of neural stem cells. The present
invention also provides cells separated from human amniotic
mesenchymal cell layer, which express nestin and musashi-1 that are
markers of neural stem cells.
[0008] By the present invention, neural stem cells which can be
supplied stably and which are free from the problem about the
compatibility in transplantation were first provided. Since the
cells according to the present invention may be collected in a
large amount together with placenta, collection of the cells is
free from the ethical problem and the cells may be supplied stably.
Further, since the cells according to the present invention have
immunological tolerance, there is no problem about the
compatibility when the cells are transplanted to a patient.
Therefore, by transplanting the cells according to the present
invention in the brain of a patient suffering from an intractable
nervous disease such as Parkinson's disease and metabolic nervous
disease, they are effective as a drug delivery system of the
substances produced by nerve cells.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] As mentioned above, the cells according to the present
invention are separated from human amniotic mesenchymal cell layer.
The mesenchymal cell layer is located between the chorionic
membrane layer and amniotic epithelial cell layer. Although
amniotic membrane is a tissue originated from the fetus, it can be
recovered in the state of being attached to placenta originated
from mother. Further, it is a large tissue which covers the entire
inner wall of uterus. Therefore, they can be obtained in a large
amount. Further, since placenta and amnion attached thereto are
discarded as medical wastes, there is no ethical problem in the
collection of amnion.
[0010] The cells according to the present invention may be
separated by peeling the amniotic epithelial cell layer+mesenchymal
cell layer of human amnion from chorionic membrane layer, treating
the resultant with trypsin to remove amniotic epithelial cells, and
by treating the resultant with a protease. Preferred examples of
the treatment with the protease include treatments with a mixture
of papain, collagenase, neutral protease+DNase (see Example below),
but not restricted thereto.
[0011] It is confirmed by immunohistostaining that cryostat
sections of amniotic membrane revealed strong immunoreactivity to
the CK19 antibody at the amniotic epithelial cell layer while
vimentin+/nestin+ cells are present at the mesenchymal cell layer.
In addition, we provided the evidence that some of cultured cells
according to the present invention express vimentin, nestin and
BrdU. Vimentin, nestin and BrdU are markers of neuronal stem cells,
and it is recognized in the art that the cell expressing these
markers are neuronal stem cell having multifunctionality (Ana villa
et al., Experimental Neurology 161.67-84 (2000)). Therefore, some
of the cells in the amniotic mesenchymal cells according to the
present invention are neural stem cells having multifunctionality.
By culturing the cells according to the present invention by
suspension culture in a culture medium containing a mitogen such as
.beta.FGF or EGF, cell spheres are formed. By recovering a part of
the sphere and suspension-culturing the recovered cells, spheres
are formed again (secondary sphere). These sphere express nestin
and musashi-1 immunohistochemically. Thus, the cells according to
the present invention may be cultured in the undifferentiated state
and are self-renewal. Further, by culturing the cells according to
the present invention in a culture medium containing B-27 (Brewer,
G. J. et al., (1993) J. Neuroscience Res. 35, 567) which is an
additive for culturing hippocampus cells, nestin and musashi-1
become negative, so that differentiation to nerve cells is
observed. B-27 is an additive for culturing hippocampus cells,
consisting essentially of biotin, L-carnitin, corticosterone,
ethanolamine, D(+)-galactose, glutathione (reduced), linolenic
acid, progesterone, putrescine, retinyl acetate, selenium, T3
(triodo-1-thyronein), DL-.alpha.-tocopherol, DL-.alpha.-tocopherol
acetate, bovine albumin, catalase, insulin, superoxide dismutase
and transferrin, and is commercially available from Invitrogen,
U.S. By culturing the cells according to the present invention by
suspension culture in a culture medium containing a mitogen such as
fibroblast growth factor (FGF) or epidermal growth factor (EGF),
cell spheres are formed. By recovering a part of the sphere and
suspension-culturing the recovered cells, spheres are formed again
(secondary sphere). Thus, the cells according to the present
invention may be cultured in the undifferentiated state and are
self-replicable.
[0012] The cultured cells obtained by primary culture or by
subsequent passage, which express nestin and musashi-1 are also
within the scope of the present invention.
[0013] The cells according to the present invention are originated
from human amnion and the amnion is originated from the fetus, so
that the cells are immunologically tolerant. That is, by
immunohistostaining, the cells according to the present invention
are HLA Class I positive and HLA Class II negative. Further, Fas
ligand-positive cells exist. Recently, it is thought that the
reason why the amniotic tissue hardly induces rejection is that HLA
Class 1b (HLA-G) is expressed and Fas ligand-positive cell exist
(Ophthalmology, 42:257-269, 2000). Thus, the cells according to the
present invention may be transplanted without the problem of HLA
compatibility.
[0014] As will be concretely described in the Example below, the
cells according to the present invention form spheres by suspension
culture, and spheres (secondary spheres) are again formed by
recovering a part of the primary sphere and suspension-culturing
the recovered cells. Therefore, the cells according to the present
invention may easily be isolated by, for example, forming secondary
spheres by suspension-culturing the nestin-positive and
musashi-1-positive cells selected from the cells separated by the
above-mentioned treatment with an enzyme mixture containing a
protease.
[0015] The spheres treated with serum-free medium containing
.beta.FGF and EGF with non-coated dishes express .beta.-tubulin as
well as nestin, indicating the cells have the neuronal
characteristics. The cells according to the present invention
differentiate to oligodendrocytes or astrocytes by being cultured
in the presence of cytokins such as NGF or NT-3 with non-coated
dishes. Further, the cells according to the present invention
differentiate to nerve cells by being cultured in the presence of
an additive for culturing hippocampus cells, such as B-27 mentioned
above. The differentiated nerve cells may be used as a source for
various substances such as dopamine and actylcholine., which are
produced by nerve cells. Dopamine is a substance known to
drastically decrease in patients suffering from Parkinson's
disease, and acetylcholine is a substance known to drastically
decrease in patients suffering from Alzheimer's disease. Further,
since the cells are immunologically naive according to the present
invention, they may be used as a drug delivery system (DDS) for
delivering dopamine, acehylcholine or the like produced by
transplanting the cells to the domain damaged in the Parkinson
disease, dementia or the like (such as basal ganglia or striatum in
case of Parkinson's disease and hippocampus in case of Alzheimer's
disease). Thus, they may be used for therapy of dementia,
Parkinson's disease, metabolic nervous disease and the like.
Further, a desired foreign gene may be introduced into the cell
according to the present invention by a known method (such as
described in Examples 1-3 of U.S. Pat. No. 6,117,676), and the
obtained cells may be used as a DDS for the substance encoded by
the foreign gene.
[0016] The present invention will now be described by way of
examples thereof. It should be noted that the Examples are
presented for the illustration purpose only and should not be
interpreted in any restrictive way.
EXAMPLE 1, COMPARATIVE EXAMPLE 1
[0017] 1. Separation and Culture of Cells
[0018] After obtaining informed consent of a pregnant mother, from
human placenta, the amniotic epithelial cell layer+mesenchymal cell
layer were obtained by separating the layers from the chorionic
membrane layer. The separated layers were treated with 0.25%
trypsin solution at 37.degree. C. for 15 minutes. After repeating
this treatment 4 times, the cells were collected by centrifuging
the trypsin solution, and the cells were washed 3 times with
phosphate buffer (PBS) (trypsin-treated fraction Comparative
Example 1)). The tissue block which was not digested by this
treatment was washed with PBS and then treated under shaking with a
mixed enzyme solution (0.01 wt % papain, 1 mg/ml collagenase, 0.01
wt % DNase, 0.1 wt % neutral protease) at 37.degree. C. for 1 hour.
The resultant was centrifuged at 1000 rpm for 10 minutes and the
obtained precipitate was suspended in PBS (mixed enzyme-treated
fraction (Example 1)).
[0019] Mixed enzyme-treated fraction was primary cultured in
DMEM:F12 (1:1) medium containing 10 wt % fetal bovine serum (FBS),
human Leukemia Inhibitory Factor (hLIF, alomone labo, Israel),
2-mercaptoethanol (2-ME, Sigma) on a culture dish coated with
collagen in an incubator containing 5% CO.sub.2 at 37.degree. C.
The DMEM:F-12 (1:1) medium used here was 1:1 mixture of Dulbecco's
modified Eagle medium (DMEM) and Ham's F-12 nutrient mixture
(F-12), and is commercially available from Sigma, USA, the mixture
being generally used as a serum-free medium for culturing mammalian
cells. The cells were then secondary cultured in the culture medium
mentioned above on a 24-well collagen-coated dish. Three to five
days later, immunostaining was performed by the method described
below.
[0020] Also, each fraction was primary cultured in DMEM:F-12 (1:1)
medium containing 10 wt % fetal bovine serum (FBS) on a culture
dish coated with collagen in an incubator containing 5% CO.sub.2 at
37.degree. C. The DMEM:F-12 (1:1) medium used here was 1:1 mixture
of Dulbecco's modified Eagle medium (DMEM) and Ham's F-12 nutrient
mixture (F-12), and is commercially available from Sigma, U.S., the
mixture being generally used as a serum-free medium for culturing
mammalian cells. Three days later, the cells reached confluency and
the cells were treated with 0.25 wt % trypsin+2.6 mM EDTA. The
cells were then secondary cultured in the culture medium mentioned
above on a 24-well collagen-coated dish. An aliquot of the culture
was separated and the culture medium was changed to DMEM:F-12 (1:1)
medium containing B-27 (50-fold diluted (final concentration) B-27
Supplement (50.times.) commercially available from Invitrogen).
Three to five days later, immunohistostaining was performed by the
method described below.
[0021] The primary cultured cells were treated with 0.25 wt %
trypsin+2.6 mM EDTA for 15 min and the resultant was suspended and
cultured in DMEM:F12 (1:1) medium containing N2 supplement
commercially available from Invitrogen (progesterone 0.63 .mu.g/ml,
putrescine 1611 .mu.g/ml, selenite 0.52 .mu.g/ml, insulin 500
.mu.g/ml, human transferring 10,000 .mu.g/ml), 20 .mu.g/ml of basic
FGF and 20 .mu.g/ml of EGF (all concentrations are expressed in
terms of final concentration). The dishes were coated by poly
2-hydroxyethyl methacrylate. Two to five days later, spheres having
diameters of 50 to 200 .mu.m were formed. The spheres were sampled
on a cover glass by using a cell-collection centrifuge, and
immunostaining was performed by the method described below. After
treating the spheres with 0.25 wt % trypsin+2.6 mM EDTA, the
resulting cells were again suspension-cultured in the medium
described above to form the secondary spheres.
[0022] To investigate the differentiation, suspension-cultured
cells were treated with several cytokines such as NT3, and NGF.
[0023] 2. Immunostaining
[0024] Acryostat section of the amniotic membrane containing
amniotic epithelial cells and amniotic mesenchymal cells was used
as well as cultured cells for immunostaining.
[0025] Immunohistostaining was carried out by a conventional method
using anti-human nestin polyclonal antibody or anti-human musashi-1
monoclonal antibody as a primary antibody, and using an anti-rabbit
IgG-rhodamine (1:100, commercially available from Chemicon) or
anti-rabbit IgG-FITC (commercially available from ZYMED) as a
secondary antibody. More concretely, the immunohistostaining was
carried out as follows: The cultured cells or amnion tissue were
fixed with 4 wt % paraformaldehyde for 1 minute and the resultant
was incubated with the above-mentioned primary antibody at room
temperature for 2 hours. The resultant was then incubated with the
secondary antibody diluted with 0.3 wt % Triton X100 (trademark) at
room temperature for 2 hours. The immunoblotted cells were observed
with a fluorescence microscope (IX 10, commercially available from
Olympus), and the confocal image obtained by using a laser scanning
microscope (Fluoview, commercially available from Olympus).
Further, using commercially available monoclonal antibodies to
other cell markers, immunohistostaining was carried out for CK19
(SANTA CRUZ), vimentin (PROGEN), Gal C (SIGMA) and .beta.-tub-III
(SIGMA) (the mentioned manufacturers are those commercializing
monoclonal antibodies to the mentioned cell markers) in the same
manner as mentioned above. Further, anti-Fas ligand antibody (SANTA
CRUZ), anti-HLA Class I antibody (HLA-A, B, C; ANSEL) or anti-HLA
Class II (HLA-DP, DQ, DR; ANSEL) was used as the primary
antibody.
[0026] The above-described culture was also carried out in the
presence of 5-bromo-2'-deoxy-uridin (BrdU) (ROCHE DIAGNOSTICS), and
BrdU positive cells were detected with commercially available kit
(ROCHE DIAGNOSTICS).
[0027] 3. Results
[0028] The immunostaining using a cryostat section of amniotic
membrane showed that CK19+ cells present only at the amniotic
epithelial cell layer and vimenin+/nestin+ cells are present at the
amniotic mesencymal cell layer.
[0029] The cells according to the present invention (Example 1)
obtained from the mixed enzyme-treated fraction, which were
cultured in DMEM:F-12 (1:1) containing hLIF, 2-ME and 10% FBS on
the collagen-coated culture dish, were mostly vimentin+, while
CK19+ cells were about 10% of the above cell fraction. The cells
characterized by vimentin+/nestin+/BrdU+ were about 15% of the
above cell fraction. As mentioned above, it is recognized in the
art that the cells expressing vimetin+/nestin+/BrdU+ are neural
stem cells. Therefore, it was proved that the some of the cells
according to the present invention are neural stem cells.
[0030] The cells according to the present invention (Example 1)
obtained from the mixed enzyme-treated fraction, which were
cultured in DMEM:F-12 (1:1) containing 10% FBS for 3 days on the
collagen-coated culture dish, were
CK19-/vimentin++/nestin+/musashi-1+/Gal C+/.beta.-tub-III+ by
immunostaining. As mentioned above, it is recognized in the art
that the cells expressing nestin and musashi-1 are neural stem
cells. Therefore, it was proved that the cells according to the
present invention are neural stem cells. The above-described
culture was also carried out in the presence of
5-bromo-2'-deoxy-uridine (5BrDU) (ROCHE DIAGNOSTICS), and 5BrDU in
the cells was detected with a commercially available kit (ROCHE
DIAGNOSTICS). The result was weakly positive, so that the cells
were in the stage of mitosis. By culturing the cells in a
B-27-containing culture medium, they were changed to
vimentin.+-./nestin-/musashi-1-/Gal C.+-./.beta.-tub-III++. Thus,
the neural stem cell markers disappeared, so that differentiation
into nerve cells was suggested.
[0031] By culturing the cells according to the present invention in
medium containing N2 supplement, basic FGF, EGF and 1% human serum
albumin (HAS), spheres with diameters of 50 to 200 .mu.m were
formed 2-5 days after the beginning of the culture with this
serum-free system. By culturing an aliquot of the spheres in the
same manner, secondary spheres were formed similarly. Thus, it was
proved that the cells according to the present invention are
self-renewal, and can be cultured in undifferentiated state in the
presence of mitogen such as .beta.FGF and EGF. On the other hand,
no spheres were formed by the cells (Comparative Example 1)
obtained from the trypsin-treated fraction. Thus, it was proved
that neural stem cells are not included in the amniotic epithelial
cells.
* * * * *